Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Long-term Surveillance of Patients With Multiple Sclerosis to Report Progressive Multifocal Leukoencephalopathy and Other Serious Opportunistic Infections Among Patients Treated With Natalizumab

NCT05236777 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT05236777
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05236777 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Long-term Surveillance of Patients With Multiple Sclerosis to Report Progressive Multifocal Leukoencephalopathy and Other Serious Opportunistic Infections Among Patients Treated With Natalizumab
Lead sponsor
Biogen
Phase
Observational
Overall status
Completed
Start date
January 1, 2019
Completion date
April 30, 2025
Enrollment
675 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis